Call For Paper

Volume 10 Issue 3

March 2024

Submit Paper Here
Download Paper Format
Copyright Form
NEWS & UPDATES
News for Authors:

We have started accepting articles by online means directly through website. Its our humble request to all the researchers to go and check the new method of article submission on below link: Submit Manuscript

Follow us on Social Media:

Dear Researchers, to get in touch with the recent developments in the technology and research and to gain free knowledge like , share and follow us on various social media. Facebook

title

TYPE OF MANUSCRIPT: REVIEW MUCORMYCOSIS ASSOCIATED WITH COVID-19: A REVIEW (CORONAVIRUS: MUCORMYCOSIS CASES SPIKE IN COVID-19 RECOVERED PATIENTS)

Author(s):

Sagar Daitkar

Keywords:

Zygomycotic Mucorales Tocilizumab Dexamethasone Diabetes CAPA

Abstract

With the onset of the second wave of coronavirus, many new symptoms and associated challenges have come to the surface. A recent report has also identified a rise in the cases of mucormycosis in COVID-19 patients, who are either hospitalised or recovering.Severe coronavirus disease (COVID-19) is currently managed with systemic glucocorticoids. Opportunistic fungal infections are of concern in such patients. While COVID-19 associated pulmonary aspergillosis is increasingly recognized, mucormycosis is rare. We describe a case of probable pulmonary mucormycosis in a 55-year-old man with diabetes, end-stage kidney disease, and COVID-19. The index case was diagnosed with pulmonary mucormycosis 21 days following admission for severe COVID-19. He received 5 g of liposomal amphotericin B and was discharged after 54 days from the hospital. We also performed a systematic review of the literature and identified seven additional cases of COVID-19 associated mucormycosis (CAM). Of the eight cases included in our review, diabetes mellitus was the most common risk factor. Three subjects had no risk factor other than glucocorticoids for COVID-19. Mucormycosis usually developed 10–14 days after hospitalization. All except the index case died. In two subjects, CAM was diagnosed post-mortem. Mucormycosis is an uncommon but serious infection that complicates the course of severe COVID-19. Subjects with diabetes mellitus and multiple risk factors may be at a higher risk for developing mucormycosis. Concurrent glucocorticoid therapy probably heightens the risk of mucormycotic. A high index of suspicion and aggressive management is required to improve outcomes.

Other Details

Paper ID: IJSARTV
Published in: Volume : 8, Issue : 4
Publication Date: 4/3/2022

Article Preview




Download Article